组蛋白去乙酰化酶：纤维化疾病的潜在治疗靶点。
Histone deacetylase: a potential therapeutic target for fibrotic disorders.
机构信息
Department of Medicine, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Middle House 301, 593 Eddy Street, Providence, RI 02903, USA.
出版信息
J Pharmacol Exp Ther. 2010 Nov;335(2):266-72. doi: 10.1124/jpet.110.168385. Epub 2010 Aug 18.
Abstract
Histone deacetylases (HDACs) are enzymes that balance the acetylation activities of histone acetyltransferases on chromatin remodeling and play essential roles in regulating gene transcription. In the past several years, the role of HDACs in cancer initiation and progression, as well as the therapeutic effects of HDAC inhibitors in various types of cancer, has been well studied. Recent studies indicated that HDAC activity is also associated with the development and progression of some chronic diseases characterized by fibrosis, including chronic kidney disease, cardiac hypertrophy, and idiopathic pulmonary fibrosis. Here, we review what is known about HDACs in the progression of tissue fibrosis and the potential applications of HDAC inhibitors in the treatment of disorders associated with fibroblast activation and proliferation.
摘要
组蛋白去乙酰化酶（HDACs）是一种在染色质重塑过程中平衡组蛋白乙酰转移酶乙酰化活性的酶，在调节基因转录中发挥着重要作用。在过去的几年中，HDACs 在癌症的发生和发展中的作用，以及 HDAC 抑制剂在各种类型癌症中的治疗效果，已经得到了很好的研究。最近的研究表明，HDAC 活性也与一些以纤维化为特征的慢性疾病的发展和进展有关，包括慢性肾脏病、心脏肥大和特发性肺纤维化。在这里，我们综述了 HDACs 在组织纤维化进展中的作用，以及 HDAC 抑制剂在治疗与成纤维细胞激活和增殖相关的疾病中的潜在应用。
相似文献
1
Histone deacetylase: a potential therapeutic target for fibrotic disorders.组蛋白去乙酰化酶：纤维化疾病的潜在治疗靶点。
J Pharmacol Exp Ther. 2010 Nov;335(2):266-72. doi: 10.1124/jpet.110.168385. Epub 2010 Aug 18.
2
The roles of histone deacetylases in kidney development and disease.组蛋白去乙酰化酶在肾脏发育和疾病中的作用。
Clin Exp Nephrol. 2021 Mar;25(3):215-223. doi: 10.1007/s10157-020-01995-5. Epub 2021 Jan 4.
3
Histone deacetylases in cardiac fibrosis: current perspectives for therapy.心脏纤维化中的组蛋白去乙酰化酶：治疗的现状展望。
Cell Signal. 2014 Mar;26(3):521-7. doi: 10.1016/j.cellsig.2013.11.037. Epub 2013 Dec 7.
4
Histone deacetylases in cardiovascular and metabolic diseases.组蛋白去乙酰化酶在心血管和代谢疾病中的作用。
J Mol Cell Cardiol. 2019 May;130:151-159. doi: 10.1016/j.yjmcc.2019.04.003. Epub 2019 Apr 9.
5
Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.靶向特发性肺纤维化中的组蛋白去乙酰化酶：未来的治疗选择。
Cells. 2022 May 12;11(10):1626. doi: 10.3390/cells11101626.
6
Therapeutic effects of histone deacetylase inhibitors on heart disease.组蛋白去乙酰化酶抑制剂治疗心脏病的疗效。
Arch Pharm Res. 2020 Dec;43(12):1276-1296. doi: 10.1007/s12272-020-01297-0. Epub 2020 Nov 27.
7
Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.I类和IIa类组蛋白去乙酰化酶在心肌肥大中的作用及靶点
J Biomed Biotechnol. 2011;2011:928326. doi: 10.1155/2011/928326. Epub 2010 Nov 29.
8
Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.I类和II类组蛋白去乙酰化酶的抑制可减轻压力超负荷引起的心脏肥大。
Circulation. 2006 Jun 6;113(22):2579-88. doi: 10.1161/CIRCULATIONAHA.106.625467. Epub 2006 May 30.
9
Therapeutic effects of histone deacetylase inhibitors on kidney disease.组蛋白去乙酰化酶抑制剂治疗肾脏疾病的疗效。
Arch Pharm Res. 2018 Feb;41(2):162-183. doi: 10.1007/s12272-017-0998-7. Epub 2017 Dec 11.
10
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.组蛋白去乙酰化酶抑制剂罗米地辛作为治疗肺纤维化的潜在药物。
Oncotarget. 2017 Jul 25;8(30):48737-48754. doi: 10.18632/oncotarget.17114.
引用本文的文献
1
Epigenetic memories induced by hypoxia in AKI-to-CKD transition.急性肾损伤向慢性肾病转变过程中由缺氧诱导的表观遗传记忆。
Clin Exp Nephrol. 2025 Aug 20. doi: 10.1007/s10157-025-02745-1.
2
The role of HDAC6 in fibrosis: a novel and effective therapy strategy.HDAC6在纤维化中的作用：一种新颖且有效的治疗策略。
Eur J Med Res. 2025 Jul 4;30(1):571. doi: 10.1186/s40001-025-02840-9.
3
Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosis.组蛋白去乙酰化酶：特发性肺纤维化的潜在治疗靶点。
Front Cell Dev Biol. 2024 Aug 13;12:1426508. doi: 10.3389/fcell.2024.1426508. eCollection 2024.
4
Chronic kidney disease activates the HDAC6-inflammatory axis in the heart and contributes to myocardial remodeling in mice: inhibition of HDAC6 alleviates chronic kidney disease-induced myocardial remodeling.慢性肾脏病激活心脏中的 HDAC6-炎症轴，并导致小鼠心肌重构：抑制 HDAC6 可减轻慢性肾脏病引起的心肌重构。
Basic Res Cardiol. 2024 Oct;119(5):831-852. doi: 10.1007/s00395-024-01056-y. Epub 2024 May 21.
5
Sirtuins and Cellular Senescence in Patients with Idiopathic Pulmonary Fibrosis and Systemic Autoimmune Disorders.Sirtuins 与特发性肺纤维化及系统性自身免疫性疾病患者的细胞衰老。
Drugs. 2024 May;84(5):491-501. doi: 10.1007/s40265-024-02021-8. Epub 2024 Apr 17.
6
Pancreatitis affects gut microbiota via metabolites and inflammatory cytokines: an exploratory two-step Mendelian randomisation study.胰腺炎通过代谢物和炎症细胞因子影响肠道微生物群：一项探索性的两步孟德尔随机化研究。
Mol Genet Genomics. 2024 Mar 16;299(1):36. doi: 10.1007/s00438-024-02125-6.
7
Synergistic Power of Piceatannol and/or Vitamin D in Bleomycin-Induced Pulmonary Fibrosis In Vivo: A Preliminary Study.白藜芦醇和/或维生素D在博来霉素诱导的体内肺纤维化中的协同作用：一项初步研究。
Biomedicines. 2023 Sep 27;11(10):2647. doi: 10.3390/biomedicines11102647.
8
Epigenetic Regulation of Fibroblasts and Crosstalk between Cardiomyocytes and Non-Myocyte Cells in Cardiac Fibrosis.心脏纤维化中，成纤维细胞的表观遗传调控以及心肌细胞与非心肌细胞之间的相互作用
Biomolecules. 2023 Sep 12;13(9):1382. doi: 10.3390/biom13091382.
9
Advances in cellular senescence in idiopathic pulmonary fibrosis (Review).特发性肺纤维化中细胞衰老的研究进展（综述）
Exp Ther Med. 2023 Feb 15;25(4):145. doi: 10.3892/etm.2023.11844. eCollection 2023 Apr.
10
A Therapeutic Perspective of HDAC8 in Different Diseases: An Overview of Selective Inhibitors.HDAC8 在不同疾病中的治疗视角：选择性抑制剂概述。
Int J Mol Sci. 2022 Sep 2;23(17):10014. doi: 10.3390/ijms231710014.
本文引用的文献
1
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.罗米地辛：一种新的皮肤 T 细胞淋巴瘤治疗药物，以及一种治疗实体瘤的潜在疗法。
Expert Rev Anticancer Ther. 2010 Jul;10(7):997-1008. doi: 10.1586/era.10.88.
2
Chemical modifier screen identifies HDAC inhibitors as suppressors of PKD models.化学修饰剂筛选发现组蛋白去乙酰化酶抑制剂可作为 PKD 模型的抑制剂。
Proc Natl Acad Sci U S A. 2009 Dec 22;106(51):21819-24. doi: 10.1073/pnas.0911987106. Epub 2009 Dec 4.
3
Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury.组蛋白去乙酰化酶调节肾小管间质损伤中的促炎和纤维化改变。
Am J Physiol Renal Physiol. 2010 Jan;298(1):F133-41. doi: 10.1152/ajprenal.00400.2009. Epub 2009 Nov 11.
4
Histone deacetylase inhibitors in cancer therapy.组蛋白去乙酰化酶抑制剂在癌症治疗中的应用。
J Clin Oncol. 2009 Nov 10;27(32):5459-68. doi: 10.1200/JCO.2009.22.1291. Epub 2009 Oct 13.
5
Histone deacetylase inhibitors: current status and overview of recent clinical trials.组蛋白去乙酰化酶抑制剂：当前状况及近期临床试验综述
Drugs. 2009 Oct 1;69(14):1911-34. doi: 10.2165/11315680-000000000-00000.
6
Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacetylase inhibition.通过抑制组蛋白脱乙酰酶消除转化生长因子-β1诱导的成纤维细胞-肌成纤维细胞分化
Am J Physiol Lung Cell Mol Physiol. 2009 Nov;297(5):L864-70. doi: 10.1152/ajplung.00128.2009. Epub 2009 Aug 21.
7
Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy.抑制组蛋白脱乙酰酶活性可减轻梗阻性肾病中肾成纤维细胞的活化和间质纤维化。
Am J Physiol Renal Physiol. 2009 Oct;297(4):F996-F1005. doi: 10.1152/ajprenal.00282.2009. Epub 2009 Jul 29.
8
Lysine acetylation targets protein complexes and co-regulates major cellular functions.赖氨酸乙酰化作用于蛋白质复合物，并共同调节主要的细胞功能。
Science. 2009 Aug 14;325(5942):834-40. doi: 10.1126/science.1175371. Epub 2009 Jul 16.
9
Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.组蛋白去乙酰化酶-2是糖尿病和转化生长因子-β1诱导的肾损伤的关键调节因子。
Am J Physiol Renal Physiol. 2009 Sep;297(3):F729-39. doi: 10.1152/ajprenal.00086.2009. Epub 2009 Jun 24.
10
Epigenetic modifications: new therapeutic targets in primary myelofibrosis.表观遗传学修饰：原发性骨髓纤维化的新治疗靶点。
Curr Stem Cell Res Ther. 2009 Dec;4(4):281-6. doi: 10.2174/157488809789649223.
Zotero 插件